GIP receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-25. Numbers and descriptions here follow the published literature rather than marketing material.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
The lichen is often found near highways and on trees growing along drainage ditches that receive runoff from fertilized fields, further supporting the role of anthropogenic nutrient enrichment in its inland establishment. The lichen grows on a range of substrates and in diverse habitats. It is found in hardwood forests within broad, low-elevation valleys and occurs sporadically on Populus and other hardwoods in riparian zones of agricultural and populated areas. It preferentially colonizes the upper parts of trunks (about 70% of total tree height), where the bark is younger and more exposed to sunlight. It is also abundant on farm buildings and on rocks immediately above the high water mark in coastal zones, and on rocky seashores it typically forms a distinct band in the supralittoral zone between more halophilic species below and terrestrial species above. Nutrient enrichment by bird droppings enhances the ability of X. parietina to grow on rock. The species demonstrates substrate versatility and has even been recorded overgrowing lead on lead-incised gravestones in England. The species demonstrates ecological resilience through its regenerative capacity. Unlike many foliose lichens that show strict positional control of growth limited to thallus margins, X. parietina can initiate new growth from virtually any damaged portion of its thallus. This ability to recover from physical damage or fragmentation allows it to persist in disturbed habitats where other lichens might fail to reestablish.
=== Pharmacodynamics === Buserelin is a GnRH agonist, or an agonist of the GnRH receptor. It is a superagonist of the GnRH receptor with potency for induction of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion of about 20 to 170 times that of GnRH itself. By activating the GnRH receptor in the pituitary gland, buserelin induces the secretion of LH and FSH from the gonadotrophs of the anterior pituitary, which travel to the gonads through the bloodstream and activate gonadal sex hormone production as well as stimulate spermatogenesis in men and induce ovulation in women. With chronic administration of buserelin however, the GnRH receptor becomes desensitized and completely stops responding both to buserelin and to endogenous GnRH. This is because GnRH is normally released from the hypothalamus in pulses, which keeps the GnRH receptor sensitive, whereas chronic buserelin administration results in more constant exposure and desensitization of the receptor. The profound desensitization of the GnRH receptor results in a loss of LH and FSH secretion from the anterior pituitary and a consequent shutdown of gonadal sex hormone production, markedly diminished or abolished spermatogenesis in men, and anovulation in women. In men, approximately 95% of circulating testosterone is produced by the testes, with the remaining 5% being derived from the adrenal glands. In accordance, GnRH analogues like buserelin can reduce testosterone levels by about 95% in men.
BJ Conagelo of /Film stated it was "fantastic to see a thoughtful and in-depth spotlight" of the work by diverse groups of women in the MCU, and found it was "equally as impressive" how much the series analyzed their impact as a "sincere assessment" of the importance of the stories beyond gender representation. Conversely, Kai Young of Screen Rant was critical of the series's lack of an episode for Scarlett Johansson's Natasha Romanoff / Black Widow.
The European Aviation Safety Agency (EASA) is tasked by Article 15(4) of Regulation (EC) No 216/2008 of the European Parliament and of the Council of February 20, 2008, to provide an annual review of aviation safety. The Annual Safety Review presents statistics on European and worldwide civil aviation safety. Statistics are grouped according to type of operation, for instance, commercial air transport, and aircraft category, such as aeroplanes, helicopters, gliders, etc. The Agency has access to accident and statistical information collected by the International Civil Aviation Organization (ICAO). States are required, according to ICAO Annex 13, on Aircraft Accident and Incident Investigation, to report to ICAO information, on accidents and serious incidents to aircraft with a maximum certificated take-off mass (MTOM) over 2250 kg. Therefore, most statistics in this review concern aircraft above this mass. In addition to the ICAO data, a request was made to the EASA Member States to obtain light aircraft accident data. Furthermore, data on the operation of aircraft for commercial air transport were obtained from both ICAO and the NLR Air Transport Safety Institute.
== Promethium-147 == Promethium-147 beta decays to the long-lived primordial radioisotope samarium-147 with a half-life of 2.6234 years, emitting low-energy beta radiation without gamma emission. It is a common fission product, produced in nuclear reactors and in trace quantities in nature, where it is also produced by the alpha decay of europium-151. In the reactor environment, it is almost exclusively produced through beta decay of neodymium-147 as usual for fission products. The isotopes 142-146Nd, 148Nd, and 150Nd are all stable with respect to beta decay, so the isotopes of promethium with those masses are not produced by beta decay and are therefore not significant fission products (as they could only be produced directly, rather than through a beta-decay chain). 149Pm and 151Pm are, but have half-lives of only 53.08 and 28.40 hours, so are not found in spent nuclear fuel that has been cooled for months or years. Promethium-147 is used as a beta particle source and a radioisotope thermoelectric generator (RTG) fuel; its power density is about 2 watts per gram. Mixed with a phosphor, it was used to illuminate the Apollo Lunar Module electrical switch tips and the control panels of the Lunar Roving Vehicle. For luminescent applications, it has generally been replaced by tritium, which is even safer and has a longer half-life (12.32 years).
Sources: en.wikipedia.org
In December 2007, Takeda submitted a New Drug Application (NDA) for alogliptin to the United States Food and Drug Administration (FDA), after positive results from Phase III clinical trials. In September 2008, the company also filed for approval in Japan, winning approval in April 2010. The company also filed a marketing authorisation application elsewhere outside the United States, which was withdrawn in June 2009 needing more data. The first NDA failed to gain approval and was followed by a pair of NDAs (one for alogliptin and a second for a combination of alogliptin and pioglitazone) in July 2011. In 2012, Takeda received a negative response from the FDA on both of these NDAs, citing a need for additional data.
Missense mutations can render the resulting protein nonfunctional, due to misfolding of the protein. These mutations are responsible for human diseases, such as Epidermolysis bullosa, sickle-cell disease, SOD1 mediated ALS, and a substantial number of cancers. Not all missense mutations lead to appreciable protein changes. An amino acid may be replaced by a different amino acid of very similar chemical properties in which case the protein may still function normally; this is termed a conservative mutation. Alternatively, the amino acid substitution could occur in a region of the protein which does not significantly affect the protein secondary structure or function. Lastly, when more than one codon codes for the same amino acid (termed "degenerate coding"), the resulting mutation does not produce any change in translation and hence no change in protein is observed; degenerate coding would be classified as a synonymous substitution, or a silent mutation, and not a missense mutation.
== Digico Micro 16 == Digico quickly started developing a general purpose 16-bit minicomputer, the Micro 16, which became available in 1966. Digico was assisted by the Ministry of Technology and the National Research Development Corporation in this development. The first version produced was the Digico Micro 16S (1968), followed by the 16P (1970), then the 16V in 1972.
Finals appearances were rare for the side, which was often in contention for the wooden spoon. Essendon did manage to make the 1968 VFL Grand Final, but it lost to Carlton by just three points and did not make it back to the big stage for 15 years. During the period from 1968 until 1980, five different coaches were tried, with none lasting longer than four years. Off the field, the club went through troubled times as well. In 1970, five players went on strike before the season even began, demanding higher payments. Essendon did make the finals in 1972 and 1973 under the autocratic direction of Des Tuddenham (Collingwood), but they were beaten badly in successive elimination finals by St. Kilda and did not taste finals action again until the very end of the decade. The 1970s Essendon sides were involved in many rough and tough encounters under Tuddenham, who himself came to loggerheads with Ron Barassi at a quarter-time huddle where both coaches exchanged heated words. Essendon had tough but talented players with the likes of Ron "Rotten Ronnie" Andrews and experienced players such as Barry Davis, Ken Fletcher, Geoff Blethyn, Neville Fields and Western Australian import Graham Moss. In May 1974, a controversial half-time all-in-brawl with Richmond at Windy Hill and a 1975 encounter with Carlton were testimony to the era. Following the Carlton match, the Herald described Windy Hill as "Boot Hill" because of the extent of the fights and the high number of reported players (eight in all — four from Carlton and four from Essendon).
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.